|Application ||IF, WB, IHC-P, FC, E|
|Calculated MW||51715 Da|
|Antigen Region||Recombinant Protein aa|
|Other Names||Muscarinic acetylcholine receptor M2, CHRM2|
|Target/Specificity||This antibody is generated from a mouse immunized with a recombinant protein.|
|Format||Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||CHRM2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then triggers calcium ion release into the cytosol.|
|Cellular Location||Cell membrane; Multi-pass membrane protein. Cell junction, synapse, postsynaptic cell membrane; Multi-pass membrane protein. Note=Phosphorylation in response to agonist binding promotes receptor internalization.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition.
Bonner T.I.,et al.Science 237:527-532(1987).
Peralta E.G.,et al.EMBO J. 6:3923-3929(1987).
Puhl H.L. III,et al.Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
Kitano T.,et al.Mol. Biol. Evol. 21:936-944(2004).
Gurevich V.V.,et al.J. Biol. Chem. 270:720-731(1995).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.